Andrenocortical carcinomas

Twelve-year prospective experience

Libuse Tauchmanovà, Annamaria Colao, Luigi Antonio Marzano, Lucianna Sparano, Luigi Camera, Annalisa Rossi, Giovanna Palmieri, Ettore Marzano, Marco Salvatore, Guido Pettinato, Gaetano Lombardi, Riccardo Rossi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I-II in 12 cases and III-IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p <0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical findingwas a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences.

Original languageEnglish
Pages (from-to)896-903
Number of pages8
JournalWorld Journal of Surgery
Volume28
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Adrenocortical Carcinoma
Carcinoma
Recurrence
Mitotane
Survival
Neoplasms
Arterial Pressure
Therapeutics
Steroids
Pharmacology
Hypertension
Drug Therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Tauchmanovà, L., Colao, A., Marzano, L. A., Sparano, L., Camera, L., Rossi, A., ... Rossi, R. (2004). Andrenocortical carcinomas: Twelve-year prospective experience. World Journal of Surgery, 28(9), 896-903. https://doi.org/10.1007/s00268-004-7296-5

Andrenocortical carcinomas : Twelve-year prospective experience. / Tauchmanovà, Libuse; Colao, Annamaria; Marzano, Luigi Antonio; Sparano, Lucianna; Camera, Luigi; Rossi, Annalisa; Palmieri, Giovanna; Marzano, Ettore; Salvatore, Marco; Pettinato, Guido; Lombardi, Gaetano; Rossi, Riccardo.

In: World Journal of Surgery, Vol. 28, No. 9, 09.2004, p. 896-903.

Research output: Contribution to journalArticle

Tauchmanovà, L, Colao, A, Marzano, LA, Sparano, L, Camera, L, Rossi, A, Palmieri, G, Marzano, E, Salvatore, M, Pettinato, G, Lombardi, G & Rossi, R 2004, 'Andrenocortical carcinomas: Twelve-year prospective experience', World Journal of Surgery, vol. 28, no. 9, pp. 896-903. https://doi.org/10.1007/s00268-004-7296-5
Tauchmanovà L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A et al. Andrenocortical carcinomas: Twelve-year prospective experience. World Journal of Surgery. 2004 Sep;28(9):896-903. https://doi.org/10.1007/s00268-004-7296-5
Tauchmanovà, Libuse ; Colao, Annamaria ; Marzano, Luigi Antonio ; Sparano, Lucianna ; Camera, Luigi ; Rossi, Annalisa ; Palmieri, Giovanna ; Marzano, Ettore ; Salvatore, Marco ; Pettinato, Guido ; Lombardi, Gaetano ; Rossi, Riccardo. / Andrenocortical carcinomas : Twelve-year prospective experience. In: World Journal of Surgery. 2004 ; Vol. 28, No. 9. pp. 896-903.
@article{805add1a9b334538b7c7d18e9505264e,
title = "Andrenocortical carcinomas: Twelve-year prospective experience",
abstract = "Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I-II in 12 cases and III-IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p <0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5{\%}) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical findingwas a recent diagnosis of moderate-to-severe hypertension (68{\%}), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences.",
author = "Libuse Tauchmanov{\`a} and Annamaria Colao and Marzano, {Luigi Antonio} and Lucianna Sparano and Luigi Camera and Annalisa Rossi and Giovanna Palmieri and Ettore Marzano and Marco Salvatore and Guido Pettinato and Gaetano Lombardi and Riccardo Rossi",
year = "2004",
month = "9",
doi = "10.1007/s00268-004-7296-5",
language = "English",
volume = "28",
pages = "896--903",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Andrenocortical carcinomas

T2 - Twelve-year prospective experience

AU - Tauchmanovà, Libuse

AU - Colao, Annamaria

AU - Marzano, Luigi Antonio

AU - Sparano, Lucianna

AU - Camera, Luigi

AU - Rossi, Annalisa

AU - Palmieri, Giovanna

AU - Marzano, Ettore

AU - Salvatore, Marco

AU - Pettinato, Guido

AU - Lombardi, Gaetano

AU - Rossi, Riccardo

PY - 2004/9

Y1 - 2004/9

N2 - Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I-II in 12 cases and III-IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p <0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical findingwas a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences.

AB - Adrenocortical carcinoma (AC) is a rare tumor with poor prognosis. Twenty-two patients (14 F, 8 M; age 22 to 59 years; median, 43 years) with AC were evaluated prospectively in a single center: tumor stage was I-II in 12 cases and III-IV in 10. The overall survival in our cohort was 41.6 ± 42 months; 16 subjects are still alive. Curative surgery was followed by longer survival than debulking or no surgery (p <0.0001). The first relapse was highly predictive for further recurrences. Recurrent ACs were progressively more aggressive, and they occurred with variable but ever shorter intervals. At diagnosis, 14 patients (63.5%) presented with features of clear adrenocortical hyperactivity. Despite the absence of clinical signs of hormonal excess, all other patients presented some abnormalities of steroid secretion. The most common clinical findingwas a recent diagnosis of moderate-to-severe hypertension (68%), poorly controlled by pharmacological treatment, often associated with multiple cardiovascular risk factors. High mitotic rate and undifferentiated polymorph cellular pattern were associated with worse prognosis. Response to treatments other than surgery (mitotane chemotherapy) was better in patients treated early after the first surgery. In conclusion, curative surgery was the most effective treatment. Monitoring arterial pressure, endocrine parameters, and metabolic parameters can be helpful for the early detection of AC recurrences.

UR - http://www.scopus.com/inward/record.url?scp=6344264964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344264964&partnerID=8YFLogxK

U2 - 10.1007/s00268-004-7296-5

DO - 10.1007/s00268-004-7296-5

M3 - Article

VL - 28

SP - 896

EP - 903

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 9

ER -